









Markets
/
Stocks
/
nasdaq-mcrb
/

Seres Therapeutics Inc

MCRB

13.960USD

+0.560+4.18%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

122.35MMarket Cap

43.17P/E TTM



Seres Therapeutics Inc

13.960

+0.560+4.18%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Seres Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Seres Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 151 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 21.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Seres Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

151 / 392

Overall Ranking

296 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Seres Therapeutics Inc Highlights

StrengthsRisks

Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 43.17, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.16M shares, decreasing 29.62% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 324.21K shares of this stock.

Analyst Rating

Based on 3 analysts

Hold

Current Rating

21.000

Target Price

+54.07%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Seres Therapeutics Inc is 8.57, ranking 40 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.57

Change



Financials

7.62

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.78

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Seres Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Seres Therapeutics Inc is 6.15, ranking 324 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 43.17, which is 2299.25% below the recent high of 1035.80 and 110.61% above the recent low of -4.58.

Score

Industry at a Glance

Previous score

6.15

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 151/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Seres Therapeutics Inc is 6.67, ranking 330 out of 392 in the Biotechnology & Medical Research industry. The average price target is 21.00, with a high of 22.00 and a low of 20.00.

Score

Industry at a Glance

Previous score

6.67

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Hold

Current Rating

21.000

Target Price

+54.07%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Seres Therapeutics Inc

MCRB

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Seres Therapeutics Inc is 5.27, ranking 325 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 15.92 and the support level at 12.49, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.06

Change

0.21

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.284

Sell

RSI(14)

40.554

Neutral

STOCH(KDJ)(9,3,3)

27.601

Neutral

ATR(14)

0.968

High Vlolatility

CCI(14)

-138.854

Sell

Williams %R

68.960

Sell

TRIX(12,20)

-0.288

Sell

StochRSI(14)

39.066

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

14.308

Sell

MA10

14.795

Sell

MA20

15.159

Sell

MA50

15.697

Sell

MA100

16.963

Sell

MA200

14.501

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Seres Therapeutics Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 23.85%, representing a quarter-over-quarter decrease of 7.15%. The largest institutional shareholder is The Vanguard, holding a total of 324.21K shares, representing 3.58% of shares outstanding, with 2.74% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Flagship Ventures

1.16M

Nestle SA

1.09M

+186.83%

The Vanguard Group, Inc.

Star Investors

311.89K

+6.78%

Marshall Wace LLP

125.60K

+37.41%

BlackRock Institutional Trust Company, N.A.

100.45K

+2.84%

Bank Vontobel AG

98.51K

+22.64%

Geode Capital Management, L.L.C.

84.98K

-7.23%

American Century Investment Management, Inc.

12.95K

+947.41%

Charles Schwab Investment Management, Inc.

31.40K

-9.96%

Citadel Advisors LLC

30.89K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Seres Therapeutics Inc is 2.03, ranking 260 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.26. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.